Pomerantz LLP is investigating Biogen and some of its executives for potential securities fraud following the company's announcement that its Alzheimer's drug trial failed to meet the primary endpoint. On May 14, 2026, Biogen reported Phase 2 trial results for diranersen, describing them as "compelling" despite missing the main dose-response target. This led to a 6.43% drop in Biogen's stock price. The investigation could impact investor confidence and lead to legal action if wrongdoing is found.
A proposed $18.9 million class action settlement has been approved by a U.S. District Court for investors who purchased Biogen Inc. common stock between June 8 and July 12, 2021. The settlement aims to resolve claims against Biogen and certain execut...
A $18.9 million class action settlement has been approved for investors who bought Biogen Inc. common stock between June 8 and July 12, 2021. The settlement resolves claims against Biogen and certain executives, with a court hearing scheduled for Sep...
Biogen announced it will showcase new data on its Alzheimer’s disease treatments at the AAIC 2026 conference in London, including Phase 2 results from the CELIA study of diranersen, a tau-targeting antisense oligonucleotide. The data includes clinica...
